AnaptysBio is dropping its atopic dermatitis (AD) drug candidate after the compound failed to reduce eczema area and itch ...

AnaptysBio has reported that the ARISE-AD trial of its investigational B and T lymphocyte attenuator (BTLA) agonist, ANB032, ...

Atopic dermatitis is a common, chronic, and flaring inflammatory skin disease characterized by persistent itch and recurrent skin lesions, and affects approximately up to 40 million people in the ...

As previously reported, Guggenheim downgraded Q32 Bio (QTTB) to Neutral from Buy and removed the firm’s prior price target following the ...

Dupilumab treatment improves signs and symptoms of atopic dermatitis (AD) in young children, according to a study p ...

Brittany Lancellotti, DVM, DACVD, offered ways veterinarians can help reduce caregiver burden in clients in an interview at the 2024 Fetch Long Beach conference ...

Brittany Lancellotti, DVM, DACVD, talks about available treatment options for flea allergies, environmental allergies, and ...

Research at National Jewish Health and other institutions has shown that the biologic dupilumab improves signs and symptoms ...

H.C. Wainwright downgraded AnaptysBio (ANAB) to Neutral from Buy with a price target of $19, down from $52, after the company announced topline ...

The prevalence of Meniere disease is higher in people with atopic dermatitis (AD), according to a study published online Nov.

Atopic dermatitis was associated with a significantly increased bipolar disorder risk among a large population-based cohort in the US.